2012-11-06 15:14:58 - Specialists in organ injury present RenaStat at ASN Kidney Week 2012

Argutus Medical, world leader in the development and manufacture of specialised organ injury tests, has been chosen as one of ten companies to display their latest product at the Innovators Place™ during the American Society of Nephrology (ASN) Kidney Week 2012.

The scientific exposition, which takes place from the 1st to the 4th of November at the San Diego Convention Center, USA, will bring together more than 13,000 professionals from around the globe to learn the latest scientific and medical advances in the field of kidney function and disease. Innovators Place™ will be located in the Kidney Week exhibit hall (Halls A-B-C) in a dedicated exhibition space that provides the opportunity for scientific networking between medical device industry trendsetters and

the nephrology community.

At the Innovators Place™, Argutus Medical, a subsidiary of EKF Diagnostics (AIM listed worldwide manufacturer of point-of-care diagnostic tools, organ injury biomarkers and assays) will showcase its new point-of-care test, the RenaStat. Renastat has been developed to detect the early onset of severe acute kidney injury (AKI) in critical care settings. Argutus’ team of AKI experts will provide attendees with an insight into the RenaStat test, as well as scientific information on the development and use of biomarkers for AKI detection.

RenaStat combines novel microfluidic and magnetic immuno-chromatographic technologies (MICT) to allow accurate detection of alpha and pi glutathione S-Transferase (GSTs) in less than 15 minutes from 100µl of patient urine. This rapid, early assessment of biomarkers enables clinicians to promptly identify and carry out appropriate patient treatment.

"Being selected to showcase at such a high profile meeting as Kidney Week 2012, is a privilege and testament to the hard work that has gone into developing RenaStat through years of research and development. Argutus representatives will be on hand to discuss with our renal medicine colleagues how the application of RenaStat can improve patient diagnosis and treatment" said Joe Keenan, General Manager at Argutus.

For more information please visit www.argutusmed.com
www.ekfdiagnostics.com